Cerebral vasodilating and vasospasmolytic action of the cerebral circulation improver 6,7-dimethoxy-1-(3,4-dimethoxybenzyl)-4-([4-(2-methoxyphenyl)-1- piperazinyl]methyl)isoquinoline in experimental animals.
Vasodilating action of a new calmodulin antagonist, 6,7-dimethoxy-1-(3,4-dimethoxybenzyl)-4-([4-(2-methoxyphenyl)- 1-piperazinyl]methyl) isoquinoline (Ro 22-4839), was examined in anesthetized animals. In anesthetized dogs, Ro 22-4839 when given intra-arterially dilated various vessels in the potency order of vertebral greater than internal carotid greater than femoral = coronary much greater than renal vessels. Ro 22-4839 (0.1-1.0 mg/kg i.v.) produced brief increases in the cerebral parietal cortex, vertebral and coronary arterial blood flows more markedly than in femoral, mesenteric and renal arterial blood flows. The compound given intraduodenally decreased the vertebral vascular resistance more extensively than the femoral one in a dose-dependent (3-30 mg/kg) way. The effect of intraduodenal administration was longer-lasting than brief action after intravenous administration, and tended to decrease heart rate. Ro 22-4839 did not significantly change cerebral oxygen consumption regardless of its increase in cerebral oxygen supply, suggesting that its cerebral vasodilating effect was due to its direct relaxing effect on the vascular smooth muscle. Papaverine and ifenprodil produced a shorter-lasting decrease in vertebral vascular resistance and caused significant tachycardia. In the video camera system monitoring the constrictory response of feline pial small vessels of the parietal cortex to hypocapnia, Ro 22-4839 was found to reverse vasoconstriction of both pial arteries and veins at the dose of 0.3 mg/kg i.v./min, which did not dilate these vessels under normocapnia. The compound uniformly reduced the pressor responses to various stimuli (electrical stimulation, norepinephrine and angiotensin II) in pithed rats.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D002415:Cats; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D003655:Decerebrate State; D004285:Dogs; D005260:Female; D006973:Hypertension / Q000503:physiopathology; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D010276:Parasympatholytics; D010646:Phentolamine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D011919:Rats, Inbred Strains; D014665:Vasodilator Agents
D007546:Isoquinolines; D010276:Parasympatholytics; D014665:Vasodilator Agents; C052931:Ro 22-4839; D011224:Prazosin; D010646:Phentolamine